# A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

> **NCT00001498** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (—)

## Conditions studied

- Breast Cancer
- Breast Neoplasms

## Interventions

- **DRUG:** methotrexate
- **DRUG:** leucovorin
- **DRUG:** 5-fluorouracil
- **DRUG:** cyclophosphamide
- **PROCEDURE:** peripheral blood progenitor cell
- **DRUG:** paclitaxel
- **DRUG:** doxorubicin

## Key facts

- **NCT ID:** NCT00001498
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-02
- **Primary completion:** —
- **Final completion:** 2000-12
- **Target enrollment:** 55 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001498, "A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00001498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*